Geneva, Switzerland and Boston, MA – December 6, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva SA to Host R&D Investor Day December 7, 2018
Geneva, Switzerland and Boston, MA – November 29, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Credit Suisse Healthcare Conference
Click here for webcast Date & Time: 15 Nov 2018 10:00 a.m. ET Location: Scottsdale, AZ
Jefferies London Healthcare Conference
Click here for webcast Date & Time: 14 Nov 2018 10:00 a.m. GMT Location: London
Q3 Report 2018
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from…
ObsEva SA to Participate in November Investor Conferences
Geneva, Switzerland and Boston, MA – November 7, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018
(GLOBE NEWSWIRE via COMTEX) –Geneva, Switzerland and Boston, MA –October 31, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN),…
Q3 2018 ObsEva SA Earnings Conference Call
Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to…